The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The challenges in primary sclerosing cholangitis – Aetiopathogenesis, autoimmunity, management and malignancy
Open accessAbstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by progressive inflammation and fibrosis of the bile ducts, resulting in biliary cirrhosis and is associated with a high risk of cholangiocarcinoma. The majority of patients are young, male and have coexisting inflammatory bowel disease. PSC is found with a prevalence of 10/100,000 in Northern European populations. The pathophysiology of PSC is a complex multistep process including immunological mechanisms, immunogenetic susceptibility and disorders of the biliary epithelia. The diagnosis is primarily based on endoscopic cholangiography although magnetic resonance imaging is increasingly used; biochemistry and immunoserology as well as histology play only a minor role. Due to the high risk of developing cholangiocarcinoma and also other tumours of the GI tract, surveillance strategies are essential, however they have yet to be established and evaluated. Biochemical parameters, clinical risk factors, endoscopic procedures and imaging techniques contribute to the early identification of patients at risk. Since medical therapy of PSC with ursodeoxycholic acid does not improve survival, to date, liver transplantation is the only option with a cure potential; if transplantation is accurately timed, transplanted PSC patients have an excellent rate of survival. However if cholangiocarcinoma is detected, a curative treatment is not possible in the majority of cases. The present review critically summarizes the current knowledge on the aetiopathogenesis of PSC and gives an overview of the diagnostic approaches, surveillance strategies and therapeutic options. Primary sclerosing cholangitis is a disease of unknown aetiology and without any further curative treatment options apart from liver transplantation. Therefore it may be regarded as the greatest challenge in hepatology today.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692 · cited 1×
“Paediatric AIH patients showed an overlap with primary sclerosing cholangitis in 49% [115].”
BackgroundNatural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394 · cited 1×
“studied 219 PSC patients in a placebo-controlled trial [163].”
BackgroundLevy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339 · cited 2×
“Also, three current retrospective studies which used higher cut-off values between 100 U/ml and 200 U/ml [124,125,130] found significant correlations with CC.”
BackgroundSerum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279
Kaplan, G. G., Laupland, K. B., Butzner, D., Urbanski, S. J., & Lee, S. S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01103.x · Cited by 273
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242 · cited 1×
“published in 2001, an improvement was documented using 20 mg/kg body weight, and 25–30 mg/kg body weight, respectively [160,161].”
MethodClinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Small-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213
Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study
Fulcher, A. S., Turner, M. A., Franklin, K. J., Shiffman, M. L., Sterling, R. K., Luketic, V. A. C., & Sanyal, A. J. (2000) · Radiology · doi:10.1148/radiology.215.1.r00ap2671 · Cited by 206
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant
Buckles, D. C., Lindor, K. D., LaRusso, N. F., Petrovic, L. M., & Gores, G. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05677.x · Cited by 194
Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis
Boberg, K. M., Jebsen, P., Clausen, O. P., Foss, A., Aabakken, L., & Schrumpf, E. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.010 · Cited by 159
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisNote
van Buuren, H. R., van Hoogstraten, H. J. F., Terkivatan, T., Schalm, S. W., & Vleggaar, F. P. (2000) · Journal of Hepatology · doi:10.1034/j.1600-0641.2000.033004543.x · Cited by 143
Broomé, U., Glaumann, H., Lindstöm, E., Lööf, L., Almer, S., Prytz, H., Sandberg-Gertzén, H., Lindgren, S., Fork, F.-T., Järnerot, G., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00036-3 · Cited by 131
Moff, S. L., Kamel, I. R., Eustace, J., Lawler, L. P., Kantsevoy, S., Kalloo, A. N., & Thuluvath, P. J. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.12.034 · Cited by 98 · cited 2×
“However, ERC remains the gold standard at least for initial diagnosis and PSC management including exclusion of malignancy of stenotic bile ducts; in particular when diagnostic or therapeutic interventions are expected, then ERC is the procedure of choice [100,101,103].”
BackgroundBiliary candida infections in primary sclerosing cholangitis
Kulaksiz, H., Rudolph, G., Kloeters-Plachky, P., Sauer, P., Geiss, H., & Stiehl, A. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.022 · Cited by 74 · cited 1×
“Numerous studies analyzed bile obtained during ERCP and found enteric bacteria [55,56] or even fungal infections with Candida [57]; yet these findings were more frequent in patients with previous ERCP and/or with dominant stenoses so that bile duct infections seemed to be more relevant for PSC progression rather than…”
Background
Cited by
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Tabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F. (2016) · Hepatology · doi:10.1002/hep.27927 · Cited by 223
“In addition to and extending these associations is a growing number of studies suggesting that the intestinal microbiota plays an important pathophysiological role in PSC, hence providing the basis of the “leaky gut” hypothesis.(1,2) The focus of these studies, though, has been on the deleterious effects of microbial…”
BackgroundAutoantibodies in primary sclerosing cholangitis
Hov, J. R., Boberg, K. M., & Karlsen, T. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3781 · Cited by 187
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis
Fosby, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.1 · Cited by 175
Barberio, B., Massimi, D., Cazzagon, N., Zingone, F., Ford, A. C., & Savarino, E. V. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.032 · Cited by 152
Metadata
- Authors
- Weismüller, T. J., Wedemeyer, J., Kubicka, S., Strassburg, C. P., & Manns, M. P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008
- Volume
- 48
- Pages
- S38-S57
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2015585189
- Cited by
- 164
- References
- 18
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.